Contrast-Enhanced Ultrasonography Features of Breast Malignancies with Different Sizes: Correlation with Prognostic Factors

Li-Xia Zhao,1,2 Hui Liu,1,2 Qing Wei,3 Guang Xu,1,2 Jian Wu,1,2 Hui-Xiong Xu,1,2 Rong Wu,1,2 and Huan Pu1,2

1Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Ultrasound Research and Education Institute, Tongji University School of Medicine, Shanghai 200072, China
3Department of Pathology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China

Correspondence should be addressed to Hui-Xiong Xu; xuhuixiong@hotmail.com and Rong Wu; 7111wurong@tongji.edu.cn

Received 30 March 2015; Revised 1 December 2015; Accepted 14 December 2015

Academic Editor: Cristiana Corsi

Copyright © 2015 Li-Xia Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was to investigate the correlation between contrast-enhanced ultrasonography (CEUS) characteristics with prognostic factors in breast cancers with different sizes. A retrospective analysis of CEUS characteristics of 104 pathologically proven malignant lesions from 104 women was conducted. Lesions were divided into two groups according to their size measured by US (Group 1: maximum diameter ≤ 20 mm; Group 2: maximum diameter > 20 mm). Features including enhancement degree, order and pattern, enlargement of the enhancement area, and penetrating vessels on CEUS were evaluated. Pathologic prognostic factors, including estrogen and progesterone receptor status, and the expression of c-erb-B2, p53, Ki-67, and VEGF were assessed. Comparison of enhancement pattern parameters between Group 1 and Group 2 showed statistically significant differences (P < 0.0001). A significant correlation was found between enlargement of the enhancement area and ER positivity in Group 1 (P = 0.032). In Group 2 the absence of penetrating vessels was significantly associated with VEGF negativity (P = 0.022) and ER negativity (P = 0.022). Centripetal enhancement reflected VEGF negativity (P = 0.033) in lesions with diameter > 20 mm. Thus, breast cancers with different sizes show different CEUS features; small breast cancers show homogeneous enhancement pattern while cancers with diameter > 20 mm show homogeneous enhancement pattern. Some CEUS characteristics of differently sized breast cancers could be correlated with prognostic factors, which may be useful in prognosis assessment.

1. Introduction

Contrast-enhanced ultrasonography (CEUS) is becoming an increasingly popular imaging tool in diagnosing breast cancer and can be performed to differentiate between benign and malignant breast lesions [1–3]. Recently, the correlation between CEUS enhancement features in breast cancers with differing prognostic factors has become a focus of intensive research [4, 5]. Previous studies have reported that the enhancement patterns and parameters of breast cancers on CUES, as a noninvasive method, could be used to predict prognosis and to identify highly aggressive breast cancers.

The ultrasound contrast agent (microbubbles) is a blood pool agent and can be used to display the imaging of microvessels. Angiogenesis is crucial for breast cancer growth, invasiveness, and metastasis and is closely related to prognosis [6, 7]. Several factors, such as larger tumor size, shorter doubling time, and higher histologic grade, are also closely related to prognosis [8]. CEUS permits the imaging of capillaries and thus is able to provide evidence toward the identification of benign and malignant breast tumors.

However, regarding the breast cancer with different sizes, its vascular structures, density, and contortion are various. Whether CEUS enhancement features also vary with tumor size remains unclear, and their potential relationship to prognostic variables is also open to debate. Answering these questions would provide a valuable contribution to the diagnosis and prognostic assessment of breast cancer and
would permit the rational design of treatment strategies at different stages of the disease; to the best of our knowledge, there is little in the current literatures on this topic. Therefore, the purpose of this study was to investigate the correlation between CEUS performance and prognostic factors in breast lesions of various sizes.

2. Materials and Methods

2.1. Patients. This retrospective study was approved by the local institutional ethics committee. Informed consent was obtained from all individual participants included in the study. Between August 2012 and July 2014, 131 patients with 133 suspicious malignant breast lesions undergoing CEUS prior to surgical management were enrolled in this study. The inclusion criteria were as follows: (1) suspicious breast lesions classified with the Breast Imaging Reporting and Data System of the American College of Radiology schema as categories 3–5, detected by conventional US or mammography; (2) CEUS examination of lesions before surgery; and (3) pathological examination of lesions after surgical resection, with all relevant prognostic indicators tested by immunohistochemical staining. Those in whom CEUS was contraindicated, as well as pregnant or breastfeeding patients, and those treated with neoadjuvant chemotherapy were all excluded from the study. All benign breast tumors pathologically proven after resection were also excluded.

Among the selected patients, 26 had benign lesions and were excluded from the study. One patient in whom CEUS clips were unsatisfactory due to the excessive influence of respiration movement was also excluded. Two patients with multiple lesions, only the most suspicious lesion meeting the inclusion criteria, were evaluated. Finally, a total of 104 lesions (from 104 patients of mean age of 57.31 ± 10.34 years; range: 33–80 years) were included in the study group.

2.2. US Examination. Conventional gray-scale US imaging was performed with the Logiq E9 US system (GE Co., Milwaukee, WI, USA) equipped with a 4–9 MHz linear transducer. All ultrasound examinations were performed by one experienced ultrasonographer with 10 years of experience in breast US and 3 years of experience in breast CEUS. All patients were scanned in the supine position. Firstly, gray-scale and color Doppler US were performed to scan the breast lesion and to observe US features such as the size, position, echogenicity, calcification, intraintralosional vascularity, and the status of axillary lymph nodes. The maximum plane which included the whole lesion and its surrounding normal tissue was selected for CEUS. Then, the US system was then switched to contrast mode for the CEUS scan. The machine parameters were adjusted as follows: mechanical index, <0.1; gain, 100–120 dB. The parameters remained the same during the examination. SonoVue (Bracco, SpA, Milan, Italy) was used as a contrast agent. 5 mL of sterile normal saline solution was injected into the vial for preparation of the contrast agent before administration; then 2.4 mL of SonoVue was injected via the antecubital vein in a bolus fashion; continuous imaging was performed immediately following this and lasted for 3 minutes. During the examination, the selected plane remained unchanged, with the probe stabilized manually. All US images and video clips were stored on a hard disk within the US machine for subsequent analysis.

2.3. Image Analysis. All US data were assessed by two ultrasound physicians with 3 and 2 years of experience in breast CEUS, respectively, who were blinded to the patients’ clinical data. If disagreement occurred, the third radiologist with 6 years of experience in breast contrast-enhanced US reviewed the image to reach an agreement. The assessment of the CEUS imaging was based on our clinical experience and the previous studies in the literatures [4].

The lesions were classified into two groups according to their sizes. Group 1 had a maximum diameter ≤20 mm, while Group 2 had a maximum diameter >20 mm. The enhancement degree was classified as hyper-, iso-, or hypoenhancement, assessed relative to the surrounding normal breast tissue at the peak time. With regard to enhancement order, centripetal enhancement was defined as enhancement originating from the periphery of the lesion and developing centripetally, while centrifugal enhancement described enhancement originating from the center of the lesion and developing centrifugally. We defined diffuse enhancement as that showing no order across the lesion. Enhancement pattern was defined as homogeneous when it uniformly and diffusely enhanced the lesion and heterogeneous when this was not the case. Perfusion defect and peripheral enhancement were also included in the latter group. Peripheral enhancement was defined as enhancement occurring exclusively or predominantly at the periphery of the lesion. Assessment of enlargement of the enhancement area involved a comparison between the largest tumorous area of the lesion at the peak time on CEUS and the corresponding tumorous area on gray-scale US; all lesions were classified as having either enlargement or nonenlargement on CEUS. Finally, the presence or absence of penetrating vessels was assessed in the maximum plane including the whole lesion and its surrounding normal tissue on CEUS.

2.4. Histopathological Analysis. All surgical samples were analyzed by two pathologists, both of whom have more than 10 years of experience in breast pathologic analysis. The histological grades were assessed according to the Elston-Ellis grading system [9]. Immunohistochemical staining was used to assess the following prognostic indicators: VEGF (MAB293; R&D System, Minneapolis, MN, USA); ER (M0241 [clone 1 D5], Changdao, Shanghai, China); PR (R0448 [clone 1 A6], Changdao, Shanghai, China); c-erb-B2 (A0485, Dako, Glostrup, Denmark); and p53 (M7001 [clone D07], Doko). For VEGF, the presence of more than 10% of cells showing staining was considered as positive. ER and PR were categorized as negative (<10%) and positive (>10%) in accordance with recent studies [10, 11]. Ki67 status was expressed in terms of the percentage of positive cells, with a threshold of 20% drawn for positivity [4, 12]. For c-erb-B2, immunohistologically Score 3 was positive, for Score 2 results...
need performing FISH testing [13]. For p53, nuclear staining defined positive expression.

2.5. Statistical Analysis. Continuous data were expressed as mean ± standard deviations. Pearson χ² test was used to explore the association between breast lesion size and CEUS enhancement. Correlation of CEUS features with prognostic factors was analyzed using the Pearson χ² test and logistic regression analysis. The level of statistical significance was set at \( P < 0.05 \). SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA) was used to perform the statistical analysis.

3. Results

3.1. Histopathological Analysis. The 104 primary breast cancers comprised 93 (89.42%) invasive ductal carcinomas, three (2.88%) ductal carcinomas in situ, two (1.92%) invasive lobular carcinomas, two (1.92%) mucinous carcinomas, three (2.88%) intraductal papillary carcinomas, and one (0.96%) metaplastic carcinoma. According to the Elston-Ellis grading system, the 93 invasive ductal carcinomas included two (2.15%) grade I tumors, 60 (64.52%) grade II tumors, and 31 (33.33%) grade III tumors. The mean size of the breast cancers was 22.51 ± 11.05 mm (5.0–74.0 mm) including 47 small cancers (≤20 mm in diameter; average: 13.64 ± 3.68 mm) and 57 large cancers (>20 mm in diameter; average: 30.77 ± 9.63 mm). The 104 malignant lesions included 69 (66.34%) that were ER positive, 64 (61.54%) that were PR positive, 70 (67.30%) that were Ki-67 positive, 81 (77.88%) that were p53 positive, 53 (50.96%) that were c-erb-B2 positive, and 54 (51.92%) that were VEGF positive.

3.2. CEUS Features of Differently Sized Breast Cancers. Comparison of enhancement pattern parameters between Group 1 and Group 2 tumors showed statistically significant differences (\( P < 0.001 \)) (Table 1). However, the differences in the enhancement degree, enhancement order, presence of penetrating vessels, and enlargement of the enhancement area between the two groups were not statistically significant (\( P > 0.05 \)). The distribution of the CEUS enhancement features and the prognostic factors is shown in Table 2.

3.3. Correlation of CEUS Features with Prognostic Factors. The association between the CEUS features of differently sized breast cancers and each prognostic factor is summarized in Table 3. In Group 1, centripetal enhancement and enlargement of the enhancement area were correlated with prognostic factors (\( P < 0.05 \)). The absence of penetrating vessels was seen in tumors with ER and VEGF negative expression in Group 2 (\( P < 0.05 \)). Centripetal enhancement showed significant correlation with VEGF negativity, and hyperenhancement was common in tumors with positive c-erb-B2 expression in Group 2 (\( P < 0.05 \)).

3.4. Logistic Regression Analysis. The results of logistic regression analysis are summarized in Table 4. For Group 1, enlargement of the enhancement area was the best discriminatory criterion for prognosis (Figure 1). For tumors > 20 mm in diameter, the absence of penetrating vessels correlated with VEGF and ER negativity and it may therefore be useful in predicting prognosis. Hyperenhancement may be useful in reflecting positive c-erb-B2 expression in Group 2, while centripetal enhancement was often found in VEGF negative lesions of maximum diameter >20 mm (Figure 2).

4. Discussion

At present, tumor prognostic factors can be assessed only in histologic specimens. VEGF plays an important role in stimulating vascular endothelial cell growth and increasing microvessel permeability [6]. Expression of VEGF and its receptor in breast cancer is associated with prognostic factors such as large tumor size and high histologic grade [14–16]. VEGF is not only an independent prognostic indicator for
Table 2: Distribution of CEUS enhancement patterns and prognostic factors.

| CEUS performance | ER1 | ER2 | PR1 | PR2 | Ki-671 | Ki-672 | P531 | P532 | c-erb-B21 | c-erb-B22 | VEGF1 | VEGF2 |
|------------------|-----|-----|-----|-----|--------|--------|------|------|----------|----------|-------|-------|
| Enhancement degree |     |     |     |     |        |        |      |      |          |          |       |       |
| Hyperenhancement  | 28  | 29  | 17  | 26  | 12    | 26     | 20   | 24   | 14       | 35       | 11    | 30    |
| Iso- or hypoenhancement | 6   | 3   | 6   | 5   | 6     | 3     | 6    | 5    | 4        | 5        | 7     | 4     |
| Enhancement order |     |     |     |     |        |        |      |      |          |          |       |       |
| Centripetal       | 20  | 12  | 24  | 11  | 21    | 12     | 13   | 17   | 15       | 26       | 9     | 23    |
| Centrifugal or diffuse | 14  | 1   | 11  | 11  | 4     | 10    | 22   | 11   | 4        | 16       | 6     | 12    |
| Penetrating vessels |     |     |     |     |        |        |      |      |          |          |       |       |
| Present           | 17  | 6   | 19  | 5   | 16    | 7     | 17   | 7    | 15       | 8        | 20    | 14    |
| Absent            | 17  | 7   | 16  | 17  | 16    | 8     | 15   | 13   | 11       | 22       | 11    | 18    |
| Enhancement pattern |     |     |     |     |        |        |      |      |          |          |       |       |
| Heterogeneous     | 6   | 5   | 21  | 16  | 7     | 4     | 20   | 17   | 6        | 5        | 29    | 8     |
| Homogeneous       | 28  | 8   | 14  | 6   | 25    | 11    | 12   | 8    | 22       | 14       | 14    | 6     |
| Enhancement area  |     |     |     |     |        |        |      |      |          |          |       |       |
| Enlargement       | 27  | 6   | 25  | 14  | 23    | 10    | 22   | 17   | 21       | 12       | 30    | 9     |
| Nonenlargement    | 7   | 7   | 10  | 8   | 5     | 10    | 8    | 7    | 12       | 6        | 9     | 5     |

Note: data are the number of cases. G1: Group 1; G2: Group 2.

Table 3: Association between CEUS characteristics and prognostic factors in the two groups.

| Enhancement degree | ER1 | ER2 | PR1 | PR2 | Ki-671 | Ki-672 | P531 | P532 | c-erb-B21 | c-erb-B22 | VEGF1 | VEGF2 |
|--------------------|-----|-----|-----|-----|--------|--------|------|------|----------|----------|-------|-------|
| Enhancement order  | 0.672 | 0.603 | 0.919 | 0.906 | 0.304 | 0.400 | 0.148 | 0.456 | 0.059 | 0.039 | 0.534 | 0.182 |
| Enhancement pattern | 0.028 | 0.161 | 0.597 | 0.197 | 0.188 | 0.897 | 0.552 | 0.603 | 0.121 | 0.847 | 0.696 | 0.030 |
| Penetrating vessels | 0.132 | 0.327 | 0.718 | 0.666 | 0.698 | 0.642 | 0.083 | 0.545 | 0.920 | 0.722 | 0.358 | 0.109 |
| Penetrating vessels | 0.813 | 0.019 | 0.831 | 0.057 | 0.440 | 0.158 | 0.932 | 0.668 | 0.770 | 0.172 | 0.292 | 0.029 |
| Penetrating vessels | 0.026 | 0.538 | 0.716 | 0.952 | 0.384 | 0.414 | 0.297 | 0.704 | 0.205 | 0.075 | 0.188 | 0.489 |

Note: data are P values (χ² test). G1: Group 1; G2: Group 2.

breast malignances but also a possible target for different therapeutic approaches [17]. Expression of the ER and PR also has a close relationship with breast tumor prognosis and the utility of hormonal therapy. Low expression of ER and PR suggests highly aggressive tumors with worse prognosis and poor response to endocrine therapy [18, 19]. The expression of the protooncogene c-erb-B2 can also predict pathogenesis and progress in breast cancer, and its overexpression is closely related to distant metastasis [20]. Meanwhile, Ki-67 is significantly correlated with tumor histologic grade and lymph node metastasis and therefore is also considered an important marker in the evaluation of tumor cell proliferative activity [18, 21, 22]. The cancer suppressor gene p53 is very susceptible to mutation in tumors and plays a critical role in cell growth and regulation [23]. Positive expression of Ki-67 and p53 reflects the ability of tumor cells to infiltrate and metastasize and thus has been related to a relatively poor prognosis.

Angiogenesis is essential for tumor cell growth and infiltration and is the basis of CEUS [24]. Pathophysiologically, some tumor cells produce large amounts of VEGF, thus generating many new tiny blood vessels [25]. However, the rate of division of malignant cells is so high that the supply of nutrients by newly formed blood vessels is soon outrunned. This may explain why our Group 2 samples evinced more heterogeneous enhancement, including perfusion defects and peripheral enhancement. In our study, the comparison of enhancement pattern parameters between Group 1 and Group 2 showed statistically significant differences (P < 0.05). In accordance with these findings, previous studies have suggested that peripheral rim enhancement on MRI is associated with larger tumor size, higher histologic grade, ER-negative status, PR-negative status, and positive lymph node status [26, 27].

We found an absence of penetrating vessels more commonly in ER-negative tumors in Group 2. A previous study has reported that penetrating vessels were a potential means for differentiating between benign and malignant breast lesions and were significantly correlated with prognosis [28]. However, in our study, the absence of penetrating vessels was seen in Group 2 breast CEUS and correlated with ER negativity. Histologic analysis of ER-negative breast cancer demonstrated that ER-negative tumors commonly show signs of central necrosis or fibrosis [29]. It is possible that such necrosis could explain the absence of penetrating vessels.

Our results show a higher ratio of centripetal enhancement and absence of penetrating vessels to VEGF negativity in tumors >20 mm in diameter. Bzyl et al. [30] reported that very small lesions show higher binding of VEGFR2-specific microbubbles than larger tumors in their experiment (P <
Table 4: The results of logistic regression analysis.

| Independent variable | B      | SE   | Wals   | 𝑃     | Exp  |
|----------------------|--------|------|--------|-------|------|
| ER\textsuperscript{G1} |        |      |        |       |      |
| Enhancement area     | 1.504  | 0.700| 4.622  | 0.032 | 4.500|
| Constant             | −0.154 | 0.556| 0.077  | 0.782 | 0.857|
| ER\textsuperscript{G2} |        |      |        |       |      |
| Penetrating vessels  | 1.396  | 0.612| 5.209  | 0.022 | 4.037|
| Constant             | −1.224 | 0.509| 5.786  | 0.016 | 0.294|
| VEGF\textsuperscript{G2} |        |      |        |       |      |
| Enhancement order    | −1.210 | 0.569| 4.531  | 0.033 | 0.298|
| Constant             | 1.056  | 0.410| 6.620  | 0.010 | 2.857|
| VEGF\textsuperscript{G2} |        |      |        |       |      |
| Penetrating vessels  | 1.396  | 0.612| 5.209  | 0.022 | 4.037|
| Constant             | −1.224 | 0.509| 5.786  | 0.016 | 0.294|

Note: G1: Group 1; G2: Group 2.

Figure 1: Images in a 70-year-old woman with a 13 mm, grade II invasive ductal carcinoma. (a) Gray-scale US image shows an irregular hypoechoic lesion. (b) Color Doppler US image shows rod-shaped blood flow. (c) CEUS image obtained 23 seconds after contrast agent injection reveals homogeneous hyperenhancement and enlargement of the affected area. (d) Histopathologic analysis demonstrates positive ER expression (original magnification, ×100).

Liu et al. [31] reported that VEGF was expressed peripherally while being centrally negative in tumors that showed peripheral enhancement. We would suggest that, with the rapid growth of tumors, the vascular formation and delivery of nutrition are relatively insufficient; thus, the center of the lesions may become hypoxic and necrotic, reducing the expression of VEGF and changing the distribution of microvessels.

The enlargement of enhancement area reflected that the breast cancers were abundant of angiogenesis. In our results, enlargement of the enhancement area was significantly associated with ER expression in Group 1 (maximum diameter ≤20 mm). Previous work showed that the region of size increased at CEUS was a sign in the diagnosis of malignant lesions [32]. For this group, lesions showing enlargement of enhancement area and homogeneous enhancement on CEUS
may be due to a balanced spatial distribution of tumor blood vessels and small lesion size. Another possible explanation may be the high degree differentiation of early breast cancers. Early detection is crucial for diagnosis, treatment, and prognosis and the CEUS feature may be conductive to the diagnosis and prognosis assessment of early breast cancer.

Our study had some limitations. First, CEUS quantitative analysis and the time-intensity curve (which may be obtained from the region of interest by special software) were not assessed. Some researchers, however, have reported that the ability of CEUS qualitative analysis to identify breast tumors is preferable to quantitative analysis [33]. Second, only the maximum plane including the whole lesion and its surrounding normal tissue was selected for CEUS. It might be argued that it would have been better to study the lesion in its entirety. Third, axillary lymph node status, an important prognostic factor used to predict breast cancer recurrence and overall survival, was not assessed in this study. Finally, the sample size was relatively small, and further studies on larger populations are needed to confirm the results.

5. Conclusions

In conclusion, breast cancers with different sizes show different CEUS features and were conducive to the prognosis assessment of the breast malignances. What is more, CEUS could reduce unnecessary biopsies or reviews and it might be used as a prognostic reference. Maybe in the future we can use the CEUS characterizations as a clue to guide treatment protocols for breast cancers with different sizes.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Li-Xia Zhao and Hui Liu are equal contributors.

Acknowledgments

This work was supported by National Natural Science Foundation of China (81471673) and the Research Project of Science and Technology Committee of Shanghai Municipality (124119a3201).

References

[1] J. Du, L. Wang, C.-F. Wan et al., “Differentiating benign from malignant solid breast lesions: combined utility of conventional ultrasound and contrast-enhanced ultrasound in comparison
with magnetic resonance imaging,” European Journal of Radiology, vol. 81, no. 12, pp. 3890–3899, 2012.

[2] C. Wan, J. Du, H. Fang, F. Li, and L. Wang, “Evaluation of breast lesions by contrast enhanced ultrasound: qualitative and quantitative analysis,” European Journal of Radiology, vol. 81, no. 4, pp. e444–e450, 2012.

[3] M. Mishima, U. Toh, N. Iwakuma, M. Takenaka, M. Furukawa, and Y. Akagi, “Evaluation of contrast Sonazoid-enhanced ultrasound for the detection of hepatic metastases in breast cancer,” Breast Cancer, 2014.

[4] C. F. Wan, J. Du, H. Fang, F. H. Li, J. S. Zhu, and Q. Liu, “Enhancement patterns and parameters of breast cancers at contrast-enhanced US: correlation with prognostic factors,” Radiology, vol. 262, no. 2, pp. 450–459, 2012.

[5] B. K. Szabó, A. Saracco, E. Táncoz et al., “Correlation of contrast-enhanced ultrasound kinetics with prognostic factors in invasive breast cancer,” European Radiology, vol. 23, no. 12, pp. 3228–3236, 2013.

[6] Y. Cao, G. E, E. Wang et al., “VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression,” Cancer Research, vol. 72, no. 16, pp. 3912–3918, 2012.

[7] A. Fantozzi, D. C. Gruber, L. Pisarsky et al., “VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation,” Cancer Research, vol. 74, no. 5, pp. 1566–1575, 2014.

[8] S. Huber, T. Helbich, J. Ketenbach, W. Dock, I. Zuna, and S. Deolme,” Effects of a microbubble contrast agent on breast tumors: computer-assisted quantitative assessment with color Doppler US—early experience,” Radiology, vol. 208, no. 2, pp. 485–489, 1998.

[9] C. W. Elston and I. O. Ellis, “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up,” C. W. Elston & I. O. Ellis. Histopathology 1991;19;403–410,” Histopathology, vol. 41, no. 3a, pp. 151–153, 2002.

[10] M. Yi, L. Hua, K. B. Koenig et al., “Which threshold for ER positivity? A retrospective study based on 9639 patients,” Annals of Oncology, vol. 25, no. 5, pp. 1004–1011, 2014.

[11] T. Iwamoto, D. Booser, V. Valero et al., “Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 729–734, 2012.

[12] F. Penault-Llorca, F. André, C. Sagan et al., “Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer,” Journal of Clinical Oncology, vol. 27, no. 17, pp. 2809–2815, 2009.

[13] A. C. Wolff, M. E. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 118–145, 2007.

[14] Y.-H. Zhou, F. Tan, K. R. Hess, and W. K. A. Yung, “The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival,” Clinical Cancer Research, vol. 9, no. 9, pp. 3369–3375, 2003.

[15] Q. Jin, K. Hemminki, K. Enquist et al., “Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis,” Clinical Cancer Research, vol. 11, no. 10, pp. 3647–3653, 2005.

[16] B. K. Lindholm, B. Lindh, L. Beckman et al., “Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers,” Clinical Breast Cancer, vol. 4, no. 5, pp. 340–347, 2003.

[17] A. D. Wagner, C. Thomssen, J. Haerting, and S. Unverzagti, “Vascular-Endothelial-Growth-Factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer,” Cochrane Database of Systematic Reviews, vol. 7, Article ID CD008941, 2012.

[18] S. Cunha, L. Gano, G. R. Morais, T. Thiemann, and M. C. Oliveira,”Progesterone receptor targeting with radiolabelled steroids: an approach in predicting breast cancer response to therapy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 137, pp. 223–241, 2013.

[19] S. Liu, S. K. Chia, E. Mehl et al., “Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients,” Breast Cancer Research and Treatment, vol. 119, no. 1, pp. 53–61, 2010.

[20] A. M. Gown, “Current issues in ER and HER2 testing by IHC in breast cancer,” Modern Pathology, vol. 21, supplement 2, pp. S8–S15, 2008.

[21] M.-Y. C. Polley, S. C. Y. Leung, I. M. McShane et al., “An international ki67 reproducibility study,” Journal of the National Cancer Institute, vol. 105, no. 24, pp. 1897–1906, 2013.

[22] N. Mori, H. Ota, S. Mugikura et al., “Luminal-type breast cancer: correlation of apparent diffusion coefficients with the Ki-67 labeling index,” Radiology, vol. 274, no. 1, pp. 66–73, 2015.

[23] A. Arjonen, R. Kaukonen, E. Mattila et al., “Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 1069–1082, 2014.

[24] R. Raja, S. Kale, D. Thorat et al., “Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis,” Oncogene, vol. 33, no. 16, pp. 2053–2064, 2014.

[25] D. J. Hicklin and L. M. Ellis, “Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis,” Journal of Clinical Oncology, vol. 23, no. 5, pp. 1011–1027, 2005.

[26] A. Poellinger, S. El-Ghannam, S. Diekmann et al., “Correlation between enhancement characteristics of MR mammography and capillary density of breast lesions,” European Journal of Radiology, vol. 83, no. 12, pp. 2129–2136, 2014.

[27] H. L. Shin, N. Cho, J. K. Seung et al., “Correlation between high resolution dynamic MR features and prognostic factors in breast cancer,” Korean Journal of Radiology, vol. 9, no. 1, pp. 10–18, 2008.

[28] X.-L. Cao, W. Bao, S.-G. Zhu et al., “Contrast-enhanced ultrasound characteristics of breast cancer: correlation with prognostic factors,” Ultrasound in Medicine and Biology, vol. 40, no. 1, pp. 11–17, 2014.

[29] T. C. Putti, D. M. Abd El-Rehim, E. A. Rakha et al., “Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis,” Modern Pathology, vol. 18, no. 1, pp. 26–35, 2005.

[30] J. Bryl, M. Palmowski, A. Rix et al., “The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55),” European Radiology, vol. 23, no. 2, pp. 468–475, 2013.

[31] H. Liu, Y. Jiang, Q. Dai, Q. Zhu, L. Wang, and J. Lu,”Peripheral enhancement of breast cancers on contrast-enhanced ultrasound: correlation with microvessel density and vascular endothelial growth factor expression,” Ultrasound in Medicine and Biology, vol. 40, no. 2, pp. 293–299, 2014.
[32] E. Aitken and M. Osman, “Factors affecting nodal status in invasive breast cancer: a retrospective analysis of 623 patients,” *Breast Journal*, vol. 16, no. 3, pp. 271–278, 2010.

[33] J. Liu, Y.-H. Gao, D.-D. Li, Y.-C. Gao, L.-M. Hou, and T. Xie, “Comparative study of contrast-enhanced ultrasound qualitative and quantitative analysis for identifying benign and malignant breast tumor lumps,” *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 19, pp. 8149–8153, 2014.